Table 1 Baseline characteristics of the study population

Demographics

Age (years)

60.65 ± 10.43

59.15 ± 13.06

0.60

Sex (n, %)

36(83.72%)

25(92.59%)

0.48

Current smoking (n, %)

29(67.44%)

16(59.26%)

0.49

Hypertension (n, %)

21(48.84%)

14(51.85%)

0.81

Diabetes (n, %)

14(32.56%)

7(25.96%)

0.56

Dyslipidemia (n, %)

14(32.56%)

10(37.04%)

0.70

Previous angina (n, %)

16(37.21%)

11(40.74%)

0.77

Admission Situation

Killip class (n, %)

I

31(72.09%)

20(74.07%)

0.86

II

10(23.26%)

6(22.22%)

-

III

1(2.33%)

1(3.70%)

-

IV

1(2.33%)

0(0%)

-

SBP (mmHg)

132.68 ± 18.66

135.83 ± 21.97

0.54

DBP (mmHg)

80.50(75.25–95.5)

90.00(73.25-92.00)

0.43

D2B (min)

75.50(50.75–89.25)

70(60–141)

0.38

P2B (min)

305(200–590)

210(140–320)

0.09

Laboratory Examination

Hb (g/L)

145 ± 16.03

144.26 ± 20.18

0.87

HbA1c (%)

5.90(5.30–6.50)

5.85(5.40–6.35)

0.96

TG (mmol/L)

1.39(0.93–2.17)

1.35(0.96–1.83)

0.82

TC (mmol/L)

4.58(3.62–5.41)

4.72(4.16–5.81)

0.40

LDL (mmol/L)

2.54 ± 0.75

2.78 ± 1.11

0.33

HDL (mmol/L)

0.96(0.89–1.20)

1.16(0.75–1.33)

0.34

Peak CK-MB (U/L)

297.50(162.75–310.50)

294.0(219.00-384.50)

0.37

Peak troponin t(ug/L)

7.30(4.54–9.90)

5.17(4.07–8.31)

0.08

BNP (pg/ml)

239.00(122.50-427.5)

230.00(58.40-479.50)

0.68

Neutrophils (10^9/L)

8.30(6.90–10.10)

7.70(6.65–10.68)

0.78

Lymphocytes (10^9/L)

1.60(1.00–2.00)

1.45(0.98–2.10)

0.91

Monocytes (10^9/L)

0.70(0.60–0.90)

0.70(0.50–0.83)

0.48

PLT (10^9/L)

167.00(138.00-221.00)

198.50(172.00-227.25)

0.14

Angiographic Characteristics

TFG (pre-PCI)

0

36(83.72%)

22(81.48%)

1.00

1

6(13.95%)

5(18.52%)

-

2

1(2.33%)

0(0%)

-

TFG (post-PCI)

3

40(93.02%)

25(92.59%)

1.00

2

3(6.98%)

2(7.41%)

-

CTFC

37.74 ± 6.92

22.89 ± 6.37

< 0.001

QFR

0.94(0.92–0.96)

0.90(0.84–0.93)

< 0.001

Culprit vessel (n, %)

LAD

36(83.72%)

22(81.48%)

1.00

LCX

2(4.65%)

1(3.70%)

-

RCA

5(11.63%)

4(14.81%)

-

Number of stents (n, %)

1

30(69.77%)

18(66.67%)

0.79

> 1

13(30.23%)

9(33.33%)

-

Total length of stents(mm)

29(18–42)

30(18–47)

0.86

Medication

Aspirin (n, %)

43(100%)

27(100%)

-

Clopidogrel (n, %)

27(62.79%)

16(59.26%)

0.77

Ticagrelor (n, %)

16(37.21%)

11(40.74%)

0.77

β-blocker (n, %)

39(90.70%)

27(100%)

0.27

ACEI/ARB (n, %)

35(81.40%)

24(88.89%)

0.62

Statins (n, %)

43(100%)

27(100%)

-